Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc demonstrated significant revenue growth in Q2, with total revenue increasing to $422K from $197K in the previous quarter, indicating a positive momentum for the company. Projections suggest continued strong revenue growth, with expectations of reaching $1.3 million in 2025 and escalating further to $4.5 million in 2026, reflecting the potential market demand for its innovative therapeutic offerings. As a clinical-stage biopharmaceutical company, RenovoRx is positioned to capitalize on its proprietary Trans-Arterial Micro-Perfusion therapy platform, which targets high unmet medical needs in cancer treatment, thus suggesting a robust outlook for future financial performance.

Bears say

RenovoRx Inc. reported revenue of $0.4 million and a net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08), which aligns with consensus estimates but highlights ongoing financial challenges. The company operates in the context of pancreatic cancer, which has an alarmingly low 5-year survival rate of only 12%, underscoring the substantial risk associated with its target market. While some growth prospects exist, the significant uncertainties in clinical advancement and financial stability contribute to a negative outlook on RenovoRx's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.